BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 33483873)

  • 1. Immunotherapy-Associated Cardiotoxicity of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor T Cell Therapy: Diagnostic and Management Challenges and Strategies.
    Stein-Merlob AF; Rothberg MV; Holman P; Yang EH
    Curr Cardiol Rep; 2021 Jan; 23(3):11. PubMed ID: 33483873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiotoxicities of novel cancer immunotherapies.
    Stein-Merlob AF; Rothberg MV; Ribas A; Yang EH
    Heart; 2021 Nov; 107(21):1694-1703. PubMed ID: 33722826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Checkpoint Inhibitor (ICI)-Related Cardiotoxicity.
    Zarifa A; Lopez-Mattei J; Palaskas NL; Iliescu C; Durand JB; Kim PY
    Adv Exp Med Biol; 2021; 1342():377-387. PubMed ID: 34972975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiotoxicities associated with immune checkpoint inhibitors.
    Yang S; Asnani A
    Curr Probl Cancer; 2018 Jul; 42(4):422-432. PubMed ID: 30173878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiotoxicity associated with immune checkpoint inhibitors and CAR T-cell therapy.
    Lipe DN; Rajha E; Wechsler AH; Gaeta S; Palaskas NL; Alhajji Z; Viets-Upchurch J; Chaftari P
    Am J Emerg Med; 2021 Dec; 50():51-58. PubMed ID: 34274878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges and solutions in management of cardiotoxicity induced by checkpoint inhibitors.
    Mladosievičová B; Országhová Z; Jablonická M; Rečková M; Chovanec M; Mego M
    Klin Onkol; 2020; 33(5):350-355. PubMed ID: 33108879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiotoxicity of Immune Checkpoint Inhibitors.
    Patel RP; Parikh R; Gunturu KS; Tariq RZ; Dani SS; Ganatra S; Nohria A
    Curr Oncol Rep; 2021 May; 23(7):79. PubMed ID: 33937956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiotoxicity of Immunotherapy: Incidence, Diagnosis, and Management.
    Asnani A
    Curr Oncol Rep; 2018 Apr; 20(6):44. PubMed ID: 29644505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiotoxicity of Contemporary Anticancer Immunotherapy.
    Dal'bo N; Patel R; Parikh R; Shah SP; Guha A; Dani SS; Ganatra S
    Curr Treat Options Cardiovasc Med; 2020; 22(12):62. PubMed ID: 33162729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxicities Associated with Immunotherapy and Approach to Cardiotoxicity with Novel Cancer Therapies.
    Gutierrez C; Rajendram P; Pastores SM
    Crit Care Clin; 2021 Jan; 37(1):47-67. PubMed ID: 33190775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiotoxicity of Immune Therapy.
    Ganatra S; Parikh R; Neilan TG
    Cardiol Clin; 2019 Nov; 37(4):385-397. PubMed ID: 31587780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular Toxicities with Chimeric Antigen Receptor T-cell Therapy.
    Gill J
    Curr Cardiol Rev; 2023; 19(1):e230622206353. PubMed ID: 35747980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiotoxicity of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Pathophysiology, Clinical Implications, and Echocardiographic Assessment.
    Nenna A; Carpenito M; Chello C; Nappi P; Annibali O; Vincenzi B; Grigioni F; Chello M; Nappi F
    Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune checkpoint inhibitor cardiotoxicity: Breaking barriers in the cardiovascular immune landscape.
    Zhu H; Ivanovic M; Nguyen A; Nguyen PK; Wu SM
    J Mol Cell Cardiol; 2021 Nov; 160():121-127. PubMed ID: 34303670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on Immunotherapy Cardiotoxicity: Checkpoint Inhibitors, CAR T, and Beyond.
    Patel M; Hudson O; Han J; Kondapalli L; Arora G; Hawi R; Andrikopoulou E; Estes C; Johnson AM; Lenneman C
    Curr Treat Options Oncol; 2023 Nov; 24(11):1489-1503. PubMed ID: 37624557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Checkpoint Inhibitors (ICIs)-Related Cardiotoxicity.
    Zarifa A; Lopez-Mattei J; Palaskas N; Iliescu C; Durand JB; Kim PY
    Adv Exp Med Biol; 2020; 1244():277-285. PubMed ID: 32301022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T-cell Immunotherapy and Cardiovascular Disease: Chimeric Antigen Receptor T-cell and Bispecific T-cell Engager Therapies.
    Stein-Merlob AF; Ganatra S; Yang EH
    Heart Fail Clin; 2022 Jul; 18(3):443-454. PubMed ID: 35718418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular toxicity of immune therapies for cancer.
    Palaskas NL; Ali HJ; Koutroumpakis E; Ganatra S; Deswal A
    BMJ; 2024 May; 385():e075859. PubMed ID: 38749554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cardiotoxicity of immune checkpoint inhibitors used in cancer treatment].
    Arangalage D; Pavon AG; Hugelshofer S; Desgraz B; Tzimas G; Delyon J; Muller O; Obeid M; Ribi C; Michielin O; Özdemir BC; Monney P
    Rev Med Suisse; 2020 Jun; 16(696):1165-1168. PubMed ID: 32496706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular Toxicities of CAR T-cell Therapy.
    Patel NP; Doukas PG; Gordon LI; Akhter N
    Curr Oncol Rep; 2021 May; 23(7):78. PubMed ID: 33937946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.